financetom
Business
financetom
/
Business
/
Apple to Keep iPhone Production in India, China, Despite Trump's Criticism, Wedbush Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Apple to Keep iPhone Production in India, China, Despite Trump's Criticism, Wedbush Says
May 26, 2025 9:38 AM

11:37 AM EDT, 05/16/2025 (MT Newswires) -- Apple ( AAPL ) will likely keep iPhone production in India and China, despite pressure from President Donald Trump to shift manufacturing of the smartphone to the US, Wedbush Securities said in a Friday client note.

The brokerage said that the tech giant could ramp up production of the iPhone in India by up to 60% to 65% by the fall in a "best-case scenario," but could pivot back to China depending upon trade talks.

During a quarterly earnings call at the beginning of this month, Apple ( AAPL ) Chief Executive Tim Cook said he expected the majority of iPhones sold in the US to have India as their source country for the ongoing three-month period, and China to be the country of origin for a "vast majority" of product sales outside the US.

Cook's comments came as the US and China raised duties on each other's goods. However, Washington and Beijing recently agreed on a 90-day suspension of tariffs.

Apple's ( AAPL ) push toward India has been a strategic move given uncertainty around tariffs on China, while trade talks with Beijing is "a major positive" for the company, Wedbush analysts led by Daniel Ives wrote in the note.

The brokerage expects the Trump administration to increase pressure on Apple ( AAPL ) to build iPhones in the US, but it said that's unlikely to materialize due to the associated costs and "Herculean-like supply chain logistics needed for such an initiative." If production were to move to the US, it could command a price tag of about $3,500 for an iPhone, according to Wedbush.

Trump said Thursday that he asked Cook to stop producing in India, according to CNBC.

Apple ( AAPL ) in February announced plans to invest more than $500 billion in the US over the next four years, including for an artificial intelligence server factory in Texas.

The brokerage maintained its outperform rating on Apple's ( AAPL ) stock and a 12-month price target of $270, reflecting its "incremental confidence in the India and China iPhone supply chain situation."

Price: 210.43, Change: -1.02, Percent Change: -0.48

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Ardelyx Opts Out of CMS Payment Adjustment for Xphozah; Shares Plunge Pre-Bell
Update: Ardelyx Opts Out of CMS Payment Adjustment for Xphozah; Shares Plunge Pre-Bell
Jul 2, 2024
08:57 AM EDT, 07/02/2024 (MT Newswires) -- (Updates with latest stock move in the headline and last paragraph.) Ardelyx ( ARDX ) said on Tuesday it decided against seeking to include its phosphate absorption inhibitor, Xphozah, in the Centers for Medicare & Medicaid Services's transitional drug add-on payment adjustment. The company said it took the decision to preserve patient access...
Jul 2, 2024
...
Lion Electric Secures New Funding; Amends Senior Credit Agreements
Lion Electric Secures New Funding; Amends Senior Credit Agreements
Jul 2, 2024
08:50 AM EDT, 07/02/2024 (MT Newswires) -- Lion Electric ( LEV ) said Tuesday that it has secured a new financing deal with Investissement Quebec worth 5 million Canadian dollars ($3.6 million). The loan, which is under Investissement Quebec's ESSOR funding program, has an initial term of three years for an annual interest rate of 13% and can be drawn...
Cartesian's Autoimmune Disorder Candidate Hits Primary Goal In Mid-Stage Study, Announces Equity Raise Of $130M
Cartesian's Autoimmune Disorder Candidate Hits Primary Goal In Mid-Stage Study, Announces Equity Raise Of $130M
Jul 2, 2024
Tuesday, Cartesian Therapeutics Inc ( RNAC ) announced topline results from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG). Descartes-08, Cartesian’s lead product candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) directed against the B cell maturation antigen. It is designed to be administered as an outpatient treatment without requiring lymphodepleting...
Copyright 2023-2026 - www.financetom.com All Rights Reserved